Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

• US 5,906,830 A
• Filed: 09/04/1996
• Issued: 05/25/1999
• Est. Priority Date: 09/08/1995
• Status: Expired due to Term

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Cygnus, Inc. (Johnson & Johnson)
• Inventors: Farinas, Kathleen C., Miller, Chad M., Soni, Pravin L.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Shelborne, Kathryne E.
• Application Number:
  US08/708,389
• Time in Patent Office: 993 Days
• Field of Search: 424/448, 424/449, 514/772.3
• US Class Current: 424/448
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61K 9/7061 Polyacrylates
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Abstract

Methods are provided for manufacturing transdermal drug delivery systems containing supersaturated drug reservoirs, such that higher drug fluxes are obtained. The methods involve heating the drug reservoir components to a predetermined temperature. Generally, this temperature is higher than the depressed melting temperature of the polymer-drug admixture which will serve as the drug reservoir. In an alternative embodiment, wherein heat treatment of the reservoir components results in a system having two liquid phases, the predetermined temperature is calculated so as to be higher than the melting temperature of the pure drug. Drug reservoirs and novel transdermal delivery systems prepared using the disclosed techniques are provided as well.

Claims

1. A method for preparing a supersaturated drug reservoir for incorporation into a transdermal drug delivery device, comprising:

(a) admixing a polymeric material and a drug formulation compatible therewith to form a drug-polymer admixture;

(b) removing substantially all solvent if present in the drug-polymer admixture;

(c) evaluating the depressed melting temperature of the drug-polymer admixture of step (b);

(d) heating the admixture prepared in step (b) to a predetermined temperature, effective to dissolve the drug in the polymeric material, wherein the predetermined temperature is above the depressed melting temperature determined in step (c); and

(e) cooling the heated admixture of step (d) to form a drug reservoir,

wherein the relative quantities of drug and polymeric material are such that the drug reservoir contains on the order of 0.1 wt. % to 20 wt. % drug.

2. The method of claim 1, wherein the drug formulation contains a solvent effective to dissolve the drug.

3. The method of claim 2, wherein the polymeric material comprises a pharmaceutically acceptable pressure-sensitive adhesive.

4. The method of claim 1, wherein the drug is selected on the basis of its capability to phase separate into a low thermodynamic activity form.

5. The method of claim 4, wherein the low thermodynamic activity form is a crystalline structure.

6. The method of claim 4, wherein the drug exists as a solid at room temperature.

7. The method of claim 4, wherein the drug is a steroid.

8. The method of claim 7, wherein the drug is selected from the group consisting of progestogens, estrogens, corticosteroids and androgens.

9. The method of claim 8, wherein the drug is selected from the group consisting of flurogestone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethisterone, norethynodrel, desogestrel, 3-keto desogestrel, gestadene, levonorgestrel, estradiol, estradiol benzoate, estradiol valerate, estradiol cyprionate, estradiol decanoate, estradiol acetate, ethynyl estradiol, estriol, estrone, mestranol, betamethasone, betamethasone acetate, cortisone, hydrocortisone, hydrocortisone acetate, corticosterone, fluocinolone acetonide, prednisolone, prednisone, triamcinolone, aldosterone, androsterone, testosterone and methyl testosterone.

10. The method of claim 9, wherein the drug is estradiol.

11. A supersaturated drug reservoir prepared by the process of claim 1.

12. A method for preparing a supersaturated drug reservoir for incorporation into a transdermal drug delivery device, comprising:

(a) admixing a polymeric material and a drug formulation to form a drug-polymer admixture;

(b) determining the depressed melting temperature of the drug-polymer admixture wherein the drug-polymer admixture is substantially solvent-free;

(c) heating the admixture prepared in step (a) to a predetermined temperature effective to dissolved the drug in the polymeric mixture, wherein the predetermined temperature is above the depressed melting temperature determined in step (b); and

(d) cooling the heated admixture of step (c) to form a drug reservoir.

13. The method of claim 12, wherein any solvent present in the drug-polymer admixture is substantially removed during step (c).

14. The method of claim 12, wherein any solvent present in the drug-polymer admixture is substantially removed prior to step (c).